Pharmaceutical Preparations · DE · CIK 1157601
Delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and advancing a pipeline of MASH treatments
Comparable business profile · signals at a glance
In the 90 days to Mar 6, 2026: 6 sold $52.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Sibold William JohnPresident and CEO | Sell | 1,663 | $431.94 | $718K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 646 | $431.94 | $279K |
| Mar 6, 2026 | Taub RebeccaDirector | Sell | 491 | $431.94 | $212K |
| Mar 6, 2026 | Huntsman CaroleChief Commercial Officer | Sell | 419 | $431.94 | $181K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 420 | $426.86 | $179K |
| Mar 6, 2026 | Kelley Shannon TGeneral Counsel | Sell | 360 | $431.94 | $155K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 160 | $434.20 | $69K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 160 | $429.00 | $69K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 120 | $430.90 | $52K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 116 | $432.56 | $50K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 80 | $436.69 | $35K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 80 | $435.32 | $35K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 80 | $427.85 | $34K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 40 | $437.65 | $18K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 40 | $429.58 | $17K |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sell | 40 | $425.08 | $17K |
| Mar 2, 2026 | Dier MardiEVP and CFO | Sell | 1,183 | $427.21 | $505K |
| Jan 26, 2026 | Sibold William JohnPresident and CEO | Sell | 1,577 | $492.42 | $777K |
| Jan 26, 2026 | Taub RebeccaDirector | Sell | 647 | $492.42 | $319K |
| Jan 26, 2026 | Huntsman CaroleChief Commercial Officer | Sell | 570 | $494.59 | $282K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.